Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2015

View Archived Issues

Met inhibition shows promising preclinical results for the treatment of nasopharyngeal carcinoma

ONCOS-102 receives FDA orphan drug status for malignant mesothelioma

Palatin initiates phase III program for bremelanotide in female sexual dysfunction

FDA grants orphan drug and rare pediatric disease designations to entrectinib for neuroblastoma

AMAG and Takeda terminate ex-U.S. ferumoxytol agreement

Repros initiates phase IIb studies of Proellex for uterine fibroids

Lilly begins phase I study of LY-3202626 in healthy subjects and Alzheimer's patients

Nippon Zoki and AnGes cancel licensing agreement

Neuren provides update on the development of NNZ-2566

Idera Pharmaceuticals provides update on IMO-8400 in Waldenstrom's macroglobulinemia

NeuroDerm reports topline results from phase IIa study of ND-0612H and ND-0612L

OncoGenex to regain rights to custirsen from Teva Pharmaceutical

Aquinox initiates phase II study of AQX-1125 for atopic dermatitis

Vaccines for Gram-negative infections described in EIT+ patent

Shanghai Institute Materia Medica patents novel RTK inhibitors

MAGL inhibitor evaluated in a mouse model of ALS

Anti-CD47 MAb demonstrate efficacy in animal models of leukemia/lymphoma

Preclinical data presented on BBI-11008 for the treatment of L-DOPA-induced dyskinesia

Investigators in Barcelona prepare and test tyrosine-protein kinase inhibitors

Asceneuron synthesizes M1 receptor PAMs

Cathepsin D inhibitors in early development at Merck KGaA

Ampla Pharmaceuticals describes GPBAR1 agonists

Roche reports cannabinoid CB2 receptor agonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Harbour Biomed closes busy year with $1B+ BMS deal
BioWorld
Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies....
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...